Dr. Scott Rocklage Likes The Old Fashion Venture Capitalism Approach

When Scott Rocklage joined 5AM Ventures in 2003, he had more than 30 years of experience in healthcare management. Scott was the President and CEO of Nycomed Salutar, and the CEO and Chairman of Cubist Pharmaceuticals. Rocklage also has an extensive research and development background. After receiving his B.S. in Chemistry from UC Berkeley, he earned his Ph.D. in Chemistry from MIT. That’s when his love of research really got started. He conducted research in Richard R. Schrock laboratory while he attended MIT. Schrock won the Nobel Prize in Chemistry in 2005. Rocklage work at MIT gave him the impetus to seek more than 30 U.S. patents during his career.

 

 

Rocklage joined 5AM Ventures because of the company’s diversified portfolio. The team at 5AM Ventures has a vested interest in companies in the medical technology, biopharmaceutical, and research sectors. Rocklage and his team evaluate product development cycles, corporate spin-offs, and innovative technologies. Scott was named managing partner in 2004. He uses the hands-on approach when the company assumes short-term operating roles, and when there is a new startup involved in the portfolio. Rocklage and his team maximize equity returns by finding non-equity capital and by creating early exit strategies. Dr. Rocklage likes to access capital from government agencies, but he also builds alliances with life science companies.

 

 

The 5AM Ventures portfolio is filled with companies that are on track to produce better-than-expected returns. Some of the companies in the 5AM portfolio are Aprea Pharmaceuticals, Biodesy, Ambrx, Alexza Pharm, Cidara Therapeutics, ENVOY Therapeutics, DVS Sciences and IKARIA Critical Care. But that is just a short list of the companies Rocklage and his team nurture in one way or another. 5AM is an early seed company, and the company has more than $1 billion in assets under management. Rocklage is a master when it comes to raising capital. Dr. Rocklage has raised over $500 million in initial public offerings in the past.

 

 

Dr. Andrew Rocklage is a member of the Massachusetts Biotechnology Council board and he is a director of MDS Proteomics Inc. He also serves on the Whitehead Institute board. His list of accomplishments also includes research and development positions at the private pharmaceutical company Catalytica, Inc., and Nycomed.

 

Leave a Reply